Erik Manting - 22 Jun 2022 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role
Director
Signature
/s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Issuer symbol
RNAZ
Transactions as of
22 Jun 2022
Net transactions value
$0
Form type
4
Filing time
22 Jun 2022, 20:24:39 UTC
Previous filing
08 Jul 2021
Next filing
10 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAZ Stock Option (Right to Buy) Award $0 +9,500 $0.000000 9,500 22 Jun 2022 Common Stock 9,500 $1.24 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.